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A B S T R A C T
The increased incidence of depression in women going through peri-menopause suggests that fluctuations in
estrogen levels may increase the risk of developing depression. Nonetheless, this psychiatric disorder is likely to
be multifactorial and consequently an additional trigger may be needed to induce depression in this population.
Stress could be such a trigger. We therefore investigated the effect of ovarian estrogen depletion and chronic
mild stress (CMS) on depressive-like behavior and brain metabolism in female rats.
Approximately 2 and 9 weeks after estrogen depletion by ovariectomy, behavioral changes were assessed in
the open-field test and the forced swim test, and brain metabolism was measured with [18F]FDG PET imaging. A
subset of animals was subjected to a 6-weeks CMS protocol starting 17 days after ovariectomy.
Short-term estrogen depletion had a significant effect on brain metabolism in subcortical areas, but not on
behavior. Differences in depressive-like behavior were only found after prolonged estrogen depletion, leading to
an increased immobility time in the forced swim test. Prolonged estrogen depletion also resulted in an increase
in glucose metabolism in frontal cortical areas and hippocampus, whereas a decrease glucose metabolism was
found in temporal cortical areas, hypothalamus and brainstem. Neither short-term nor prolonged estrogen de-
pletion caused anxiety-like behavior. Changes in body weight, behavior and brain glucose metabolism were not
significantly affected by CMS.
In conclusion, ovarian estrogen depletion resulted in changes in brain metabolism and depressive-like be-
havior, but these changes were not enhanced by CMS.
1. Introduction
Depression is a common mental disorder with symptoms like loss of
pleasure or interest in daily life activities (anhedonia), poor con-
centration, decreased energy, insomnia or hypersomnia, weight loss or
gain, and others (Post and Warden, 2018). These symptoms may result
in poor quality of life, accompanied by a decrease in productivity and
increased mortality from suicide (WHO, 2017). This neuropsychiatric
disorder is currently the leading cause of disability in the world, with
more than 300million people being affected (WHO, 2017).
Epidemiological studies of depression have shown that the disease is
twice as common in women as in men (Kessler et al., 1993; Weissman
et al., 1984). Recent evidence suggests that estrogens play an important
role in the pathophysiology of depressive disorders in women (Schmidt
et al., 2015; Slowik et al., 2017; Whooley et al., 2000). This could ex-
plain the increased risk for women to develop depression during per-
iods of hormonal changes, such as pre-menstrual, during pregnancy and
post-partum, and both peri- and post-menopausal periods (Bloch et al.,
2015; Deecher et al., 2008; Georgakis et al., 2016; Gordon et al., 2015;
Schmidt et al., 1998; Vivian-Taylor and Hickey, 2014).
Thus, the increased risk for women during peri-menopause to de-
velop depression, could be explained by the decline in circulating es-
trogens (Grochans et al., 2018; Schmidt et al., 2015; Soares, 2017).
However, since only a minority of women with ovarian estrogen
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depletion suffer from depression (Soares, 2014), it seems plausible that
the incidence of depression in postmenopausal women depends not
only on estrogen levels, but probably also requires an additional trigger.
Stress might be such a trigger; demographic studies suggest that
stressful life events during the transition to menopause could contribute
to the development of depression (Cohen et al., 2006; Hankin and
Abramson, 2001; Schmidt et al., 2004). Therefore, we hypothesized
that the combination of stressful life events and declining estrogen le-
vels may culminate in a higher incidence of depression.
The objective of this study was therefore to determine whether
chronic mild stress (CMS) during a period of estrogen depletion affects
the susceptibility of female rats to develop depressive-like behavior.
Ovariectomy was performed to decrease circulating estrogen levels in
female rats. Two weeks after ovariectomy, the animals were exposed to
a 6-weeks CMS protocol, involving continuous exposure to a variety of
mild stressors, known to induce learned helplessness, a core symptom of
depression in humans (Willner, 2005). Depressive-like behavior was
assessed in the open-field test and the forced swim test before and after
the CMS protocol. In addition, [18F]FDG PET scans were performed as a
marker of brain metabolism. Changes in brain metabolism have been
related to hormonal changes and depressive-like behavior (Coyoy and
Universitaria, 2016; Ernst et al., 2002; López and Tena-Sempere, 2015;
Santiago et al., 2016; Silverman et al., 2011). In fact, clinical [18F]FDG
PET imaging studies have shown that glucose metabolism is affected in
various parts of the brain of depressive patients (Su et al., 2014).
2. Materials and methods
2.1. Animals
Female outbred Wistar rats (n=32, 9–12 weeks old, 200−250 g)
were purchased from Harlan (Horst, The Netherlands). Animals were
housed individually in Macrolon cages filled with wood shavings,
placed in a room with a constant temperature (21 ± 2 °C) and a fixed
12-h light-dark regime. Standard laboratory chow and water were
available ad libitum. After arrival, rats were acclimatized for at least 7
days. During acclimatization and throughout the study, all rats were
handled daily. All experiments were approved by the Institutional
Animal Care and Use Committee of the University of Groningen, The
Netherlands (study protocol: DEC 5842D).
2.2. Study design
The timeline of experimental procedures is depicted in Fig. 1. All
rats were ovariectomized and divided into two treatment groups, pla-
cebo (VEH) and estradiol (EST), and further divided into two condition
groups, animals without (CTL) and with exposure to chronic mild stress
(CMS) for six weeks. This lead to four different groups of 8 ovar-
iectomized animals: placebo alone (VEH+CTL), estradiol replacement
(EST+CTL), placebo in combination with stress (VEH+CMS), and
estradiol replacement in combination with stress (EST+CMS).
On day 0 the rats were ovariectomized and either a placebo or an
estradiol releasing pellet was implanted. Rats were allowed to recover
from the surgery for 12 days. On day 13, a [18F]FDG PET scan was
performed, followed by an open field test (OFT) on day 14 and the
forced swim test (FST) on days 15 (pretest) and 16 (test). Between day
17 and day 59 (6 weeks), half of the rats were exposed to mild stressors
according to the CMS protocol (Table 1). Control animals were not
exposed to these stressors. On day 60, all rats were subjected to another
[18F]FDG PET scan, followed by an OFT on day 61, and FST on day 62
(pretest) and 63 (test). Immediately after the last FST test, all animals
were sacrificed and the brain, uterus and adrenal glands were dissected.
2.3. Ovariectomy and estradiol replacement
Bilateral ovariectomy was performed under isoflurane anesthesia as
previously described (Khayum et al., 2014). Both sides of the abdomen
were shaved and sterilized with 70 % ethanol. A small incision was
made in the skin and muscle layer of the abdomen to expose the
ovaries. The blood vessels that supply the ovaries were ligated with silk
sutures and the ovaries with the associated fat pads and a part of the
uterus were removed. The muscle layer and the skin were then closed
with chromic sutures.
Immediately after ovariectomy, a placebo pellet or an estradiol-re-
leasing pellet (NC-111 Placebo, and NE-121 17ß-estradiol 2.25mg/
pellet, 90 day release, Innovative research of America, Florida, USA)
was subcutaneously implanted in the neck of the rat. Estradiol pellets
released 25 μg of estradiol per day with zero order kinetics, generating
Fig. 1. Study design. On day 0 rats were ovariectomized (OVX) and implanted with either an estradiol or vehicle releasing pellet. After 12 days of recovery, rats
were exposed to a baseline PET scan and behavioral tests (OFT: open field test, pFST: pre-forced swim test, tFST: test forced swim test). On day 17, animals were
exposed to chronic mild stress (CMS) for 6 weeks. After the CMS protocol, the PET scan, OFT, pFST and tFST were repeated.
Table 1
Chronic mild stress protocol. Chronic mild stress (CMS) was induced during 6
weeks, with fixed stressors every day.
Day Stressors
Sunday 20:00 h: Paired housing for 14 h
Monday 10:00 h: Tilting of the cages (45°) for 10 h
20:00 h: Soiled cage (250ml of water was poured into the sawdust
bedding) for 14 h
Tuesday 10:00 h: Cage cleaning, followed by water deprivation for 10 h
20:00 h: Paired housing for 14 h
Wednesday 10:00 h: Stroboscopic illumination in darkness for 10 h
20:00 h: Food deprivation for 14 h
Thursday 10:00 h: Tilting of the cages (45°) for 10 h
20:00 h: Cages were put back in straight position. Animals were
allowed a period without exposure to a stressor
Friday 10:00 h: Stroboscopic illumination in darkness for 10 h
20:00 h: Soiled cage (250ml of water was poured into the sawdust
bedding) for 14 h
Saturday 10:00 h: Cage cleaning followed by no stress
20:00 h: Food and water deprivation for 14 h
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physiological levels of estradiol in plasma. After surgery, the rats were
subcutaneously injected with finadyne (2.5.mg/kg Flunixin, Schering-
Plough N.V/S.A., Belgium) for pain relief. Administration of finadyne
was repeated 24 h after surgery. Rats were weighed weekly to monitor
body weight changes.
2.4. Chronic mild stress
The CMS protocol started on day 17 and consisted of 6 weekly cy-
cles of exposure to different stressors (Table 1), as described elsewhere
(Dalla et al., 2005; Dioli et al., 2019; Grippo et al., 2005; Pitychoutis
et al., 2012). The stressors were as follows: paired housing (each rat 6x
acted as a resident and 6x as an intruder), tilting of cages to 45°, soiled
cage, stroboscopic illumination (1500W, 2 flashes per second), and
food and water deprivation. Control rats were housed in a separate
room, and were not exposed to these stressors.
2.5. Open field test
The open field test was performed twice on days 14 and 61. Animals
were placed in the center of a circular black arena (diameter 80 cm,
height 40 cm) and were allowed to explore for 5min. During this
period, behavior was videotaped for subsequent behavioral analysis.
After each open field experiment, the arena was cleaned with water and
70 % alcohol. Videos were analyzed using Ethovision XT 8 (Noldus
Information Technology, Wageningen, The Netherlands). The outcome
parameters were the total distance traveled by the animal (locomotion)
and the time spent in a central circular area with a 40 cm diameter
(anxiety).
2.6. Forced swim test
On day 15 and 62, animals were subjected to a pretest FST. Rats
were individually placed in a cylindrical water tank (diameter 20 cm;
height 40 cm) for 15min. The water level in the tank was set at 30 cm to
ensure the rats could swim or float without touching the bottom of the
tank with their hind limbs. Water temperature was maintained at
21 ± 1 °C. After 15min, animals were taken out of the cylinder. On
day 16 and 63, rats were subjected to the test FST by placing the ani-
mals in the cylinder filled with water, under the same conditions as in
the pretest, but only for 5min. After every exposure to the cylinder, rats
were dried with paper towels and returned to their home cages. After
every session, water from the tank was discarded; the tank was washed
and filled with fresh water for the next test. The entire pretest and test
FST sessions were recorded on video for subsequent analysis using
Ethovision XT 8 software (Noldus Information Technology,
Wageningen, The Netherlands).
Floating and high locomotion time were used as outcome para-
meters of helplessness. Floating was defined as less than 2 % change in
body surface area, while highly locomotion was defined as more than
12 % change in body surface area. Parameters were measured in a
5min exposure to the FST cylinder.
2.7. [18F]FDG PET imaging
On days 13 and 60, animals were subjected to an [18F]FDG PET
scan. Rats were placed in cages with a temperature of 30 °C for en-
vironmental adaptation and minimization of [18F]FDG uptake in brown
fat. After 30min of adaptation, rats were anesthetized with isoflurane
(5 % induction and 2 % maintenance, in medical air) and injected with
[18F]FDG via the tail vein (14.5 ± 2.5MBq). Rats were allowed to
recover from anesthesia in their cages. Forty min after injection, the
rats were again anesthetized with isoflurane and placed in a small an-
imal PET camera (Focus 220, Siemens Medical Solutions, USA, Inc).
Rats were placed in a transaxial position with their heads inside the
field of view. 45min after [18F]FDG injection, a 30min static PET scan
was acquired. During the PET scan, rats were kept under isoflurane
anesthesia (2 % in medical air) and body temperature was maintained
by heating pads. Eye salve was used to prevent dehydration of the eyes.
After completion of the emission scan, a transmission scan with a 57Co
point source was acquired for 515 s to allow correction of attenuation
and scatter by tissue. List mode emission data was iteratively re-
constructed into a single frame image of 30min (OSEM2D, 4 iterations,
and 16 subsets). PET data were normalized and corrected for attenua-
tion, scatter, random coincidences and radioactive decay.
2.8. PET analysis
To determine global and region-of interest differences in [18F]FDG
brain uptake, volumes of interest (VOI) were drawn on a [18F]FDG
brain template that was co-registered with the PET images. Region of
interest (ROI) analysis was performed with a brain template including
the following areas of interest: amygdala, bed nucleus stria terminalis,
brainstem, cerebellum, frontal cortex, hippocampus, hypothalamus,
insular cortex, midbrain, occipital cortex, olfactory cortex, parietal
cortex, striatum, temporal cortex, thalamus and whole brain. The VOIs
from the template were copied to the individual PET images to de-
termine the accumulation of radioactivity in the whole brain and in-
dividual brain regions (in Bq/cm3). [18F]FDG uptake was corrected for
body weight and injected dose and expressed as the standardized up-
take value (SUV). The SUV was defined as: [tissue activity concentra-
tion (Bq/cm3)]/[injected dose (Bq)/body weight (g)]. It was assumed
that 1 cm3 of brain tissue equals 1 g.
2.9. Statistical analysis
All data is expressed as mean ± standard error of the mean (SEM).
All statistical analyses were performed using IBM SPSS statistics 22 for
Windows. Body weight changes, behavioral changes (OFT and FST),
and [18F]FDG uptake (expressed as SUV) were analyzed using a General
Estimated Equation model (GEE). Between-group and within-group
differences were assessed using the factors: treatment (estradiol vs.
placebo), condition (chronic mild stress vs. control) and time.
Additionally, to determine the interaction between estrogen depletion
(EST) and chronic mild stress (CMS), an interaction analysis was per-
formed with the model using the data of the scans performed after the
CMS protocol.
For analysis of adrenal gland and uterus weight changes, data was
normalized to body weight, and analyzed using one-way ANOVA and
Bonferoni as post-hoc test. For all statistical analyses, significance was
assumed when the probability (p) was<0.05. Moreover, effect sizes
were estimated for all PET analyses, using the d index, which is defined
as:
Cohen’s d = (M2 – M1) / SDpooled
where
SDpooled = √((SD12 + SD22) / 2)
3. Results
3.1. Physiological parameters
Body weight was measured weekly in order to assess the effect of
estrogen depletion and CMS. Within-group differences in body weight
gain over time were observed in all experimental groups (Fig. 2A;
p < 0.001), although at different rates. Significant differences between
groups were first found on day 10 (i.e. before the CMS protocol;
Fig. 2A), with animals receiving estrogen replacement (EST+CTL
-4.7 ± 1.2 g; EST+CMS -4.8 ± 0.8 g) showing significantly
(p < 0.001) less body weight gain than estrogen-depleted animals
(VEH+CTL 1.5 ± 0.5 g; VEH+CMS 1.2 ± 0.7). At the end of the
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experiment, the increase in body weight in animals with estradiol re-
placement, as compared to estrogen-depleted animals, was even more
pronounced (EST+CTL 10.4 ± 7.0 g vs. VEH+CTL 56.2 ± 5.7 g,
p < 0.001; EST+CMS 8.1 ± 3.4 g vs. VEH+CMS 48.6 ± 4.7 g;
p < 0.001). No effect of stress alone was found at any time point, when
comparing the VEH+CTL group vs. the VEH+CMS group or the
EST+CTL group vs. the EST+CMS group.
The weight of the uterus, normalized for body weight, was mea-
sured at the end of the experiment (day 63), as an indicator of changes
in circulating estrogen levels (Fig. 2B). Estrogen depletion had a sig-
nificant effect on uterus weight, resulting in a significantly (p < 0.001)
lower uterus weight in the estrogen-depleted animals (VEH+CTL
0.7 ± 0.10 g/kg; VEH+CMS 0.7 ± 0.10 g/kg) than in the estradiol-
treated groups (EST+CTL 3.3 ± 0.38 g/kg; EST+CMS
3.1 ± 0.48 g/kg). Uterus weight was not affected by CMS.
The adrenal gland weight, normalized to body weight, was mea-
sured to assess the effect of chronic activation of the hypothalamus-
pituitary-adrenal (HPA) axis by stress (Fig. 2C). Estrogen depletion
induced shrinkage of the adrenal gland, resulting in a significantly
lower adrenal gland weight in estrogen-depleted animals than in the
estradiol replacement group that was not exposed to CMS, (EST+CTL
0.35 ± 0.05 g/kg vs. VEH+CTL 0.20 ± 0.02 g/kg, or VEH+CMS
0.21 ± 0.02 g/kg; F= 1.09, p < 0.05, p < 0.01, respectively). The
adrenal gland weight of the EST+CMS group (0.31 ± 0.02 g/100 g)
was not significantly different from any of the other groups. No effect of
CMS on adrenal gland weight was observed.
These results show that estrogen depletion increased body weight
and reduced uterus and adrenal gland weight, whereas CMS did not
have any effect on these parameters.
3.2. Behavioral tests
3.2.1. Open field test
The OFT was used to determine motor activity and anxiety-like
behavior. Time spent in the center of the arena was used as a measure of
anxiety-like behavior (Fig. 3A–B). No significant effects of estrogen-
depletion on the total time spent in the center was found on day 14 (EST
16.6 ± 8.7 s; VEH 24.9 ± 5.9 s). On day 61, no significant effects of
estrogen-depletion or CMS on anxiety-like behavior were observed ei-
ther (EST+CTL 16.1 ± 4.3 s; EST+CMS 26.0 ± 9.9 s; VEH+CTL
20.7 ± 4.7 s; VEH+CMS 18.1 ± 7.1 s). There were also no sig-
nificant changes between day 14 and 61 in any group.
On day 14, there was no effect of estrogen-depletion on locomotion,
measured as total distance moved (EST+CTL 15.5 ± 2.2m;
VEH+CTL 13.3 ± 1.0m). No significant differences in distance
moved between groups were found on day 61 either (EST+CTL
12.6 ± 2.1m; EST+CMS 15.0 ± 3.7 cm; VEH+CTL 14.0 ± 1.7m;
VEH+CMS 11.6 ± 2.3m). No effects of time or treatment on motor
activity were found in a within-group comparison analysis (Fig. 3C–D).
So, neither estrogen depletion nor CMS affected motor activity or
anxiety-like behavior in the OFT.
3.2.2. Forced swim test
Floating time was used as a parameter of learned helplessness in the
FST (Fig. 3E–F). No effect of estrogen depletion on floating time was
found on day 16 (EST 41.8 ± 5.6 s; VEH 29.1 ± 8.1 s). Nonetheless,
an increase in floating time due to estrogen depletion was found in
stress naïve animals on day 63 (EST+CTL 26.8 ± 10.6 s; VEH+CTL
99.2 ± 36.5 s; p < 0.05). In animals that underwent the CMS pro-
tocol, a similar trend was observed, although the effect of estrogen
depletion in these animals was not statistically significant yet
(EST+CMS 25.3 ± 9.8 s; VEH+CMS=63.5 ± 23.8 s). No effect of
CMS on floating time was observed.
High locomotion was measured as a state of motivation of the an-
imal to escape from the cylinder (Fig. 3G–H). Short-term effects of es-
trogen depletion on high locomotion could not be detected on day 16,
but significant long term effects of estrogen depletion were found on
day 63 (EST+CTL 66.1 ± 15.9 s; EST+CMS 68.7 ± 9.5 s;
VEH+CTL 21.6 ± 5.4 s; VEH+CMS 34.9 ± 7.0 s; p < 0.01). No
significant effect of stress alone was observed.
Thus, estrogen depletion seems to increase learned helplessness and
decrease motivation in the FST, whereas CMS did not have any effect.
3.3. [18F]FDG PET
3.3.1. Regional glucose metabolism changes 13 days after OVX
Whole brain [18F]FDG uptake, as a surrogate biomarker of cerebral
glucose metabolism, is shown in Fig. 4A–B. A statistically significant
increase in whole brain [18F]FDG uptake between estradiol- and pla-
cebo-treated rats was found on day 13 (p < 0.05; EST SUV=2.3 ±
0.1; VEH SUV=2.05 ± 0.1). ROI analysis showed that after 13 days
of estrogen depletion, placebo-treated rats presented a decrease in
glucose metabolism in several areas, including midbrain, hippocampus,
thalamus, cerebellum, brainstem, frontal cortex, striatum, insular
cortex and bed nucleus stria terminalis, when compared to estradiol-
treated animals (Table 2, p < 0.05, p < 0.001).
3.3.2. Regional glucose metabolism changes after CMS
Changes in brain glucose metabolism on day 60 are presented in
Fig. 4C–D. No statistically significant effects of treatment (placebo or
estradiol), condition (control or CMS) or interaction between treatment
and condition in whole brain [18F]FDG uptake were found (EST+CTL
SUV=2.1 ± 0.1; EST+CMS SUV=2.4 ± 0.2; VEH+CTL
SUV=2.1 ± 0.1; VEH+CMS SUV=2.1 ± 0.1). On day 60, es-
trogen depletion alone induced significant differences in brain meta-
bolism (Table 3). When comparing groups without CMS (EST+CTL vs
VEH+CTL), significantly higher [18F]FDG uptake was found in the
insular cortex of rats with estradiol treatment, when compared to ve-
hicle control animals (p < 0.05). When comparing groups with CMS
(EST+CMS vs VEH+CMS), a higher uptake was found in both frontal
Fig. 2. Physiological parameters. A. Body weight changes during the experiment (n=8 per group). B. Normalized changes in the uterus weight at the end of the
experiment (EST+CTL n=8; EST+CMS n=6; VEH+CTL n=8; VEH+CMS n=6). C. Normalized adrenal gland weight changes after all experimental
procedures (EST+CTL n=7; EST+CMS n=8; VEH+CTL n=8; VEH+CMS n=8). Data is presented as mean ± SEM. Statistically significant differences
between groups are indicated as: *p < 0.05; **p < 0.01 and ***p < 0.001. Differences within groups are indicated as ### p < 0.001.
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Fig. 3. Behavioral analysis. A. Time spent in the center in the open field test (OFT) at day 14 (n=16 per group). B. Time spent in the center in the open field test
(OFT) at day 61 (n=8 per group). C. Locomotion during the OFT at day 14 (n= 16 per group). D. Locomotion during the OFT at day 61 (n=8 per group). E.
Floating time as a measure of immobility in the forced swim test (FST) at day 16 (n=15 per group). F. Floating time as a measure of immobility in the forced swim
test (FST) at day 63 (EST+CTL n=6; EST+CMS n=7; VEH+CTL n=7; VEH+CMS n=7). G. Time that the animals attempt to escape from the cylinder,
defined as highly mobile state of the animals in the FST at day 63 (n=15 per group). H. Time that the animals attempt to escape from the cylinder, defined as highly
mobile state of the animals in the FST at day 63 (EST+CTL n=6; EST+CMS n=7; VEH+CTL n=7; VEH+CMS n=7). Data is presented as mean ± SEM.
Statistically significant difference are indicate by: *p < 0.05; **p < 0.01 and ***p < 0.001.
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cortex and thalamus (p < 0.05). In addition, the combination of OVX
and CMS (EST+CMS vs VEH+CTL) induced an increase in brain
metabolism in the insular cortex (p < 0.05).
In contrast, statistical analysis of individual brain regions revealed
no differences in brain metabolism due to CMS treatment alone
(VEH+CTL vs. VEH+CMS or EST+CTL vs. EST+CMS). In addi-
tion, no significant interaction between chronic mild stress and es-
trogen depletion (EST*CMS, p > 0.05) was observed in any of the
brain areas tested.
3.3.3. Within group regional metabolism changes
Within group analysis of the differences between the PET scans at
day 13 and 60 showed no significant differences in the EST+CMS,
VEH+CTL and VEH+CMS groups. However, a significant decrease in
FDG uptake was found in the brainstem of EST+CTL when comparing
day 13 and 60 (Table 4, p < 0.05). An additional analysis, testing the
effects of estradiol alone (EST+CTL and EST+CMS vs VEH+CTL
and VEH+CMS) or chronic stress alone (EST+CMS and VEH+CMS
vs EST+CTL and VEH+CTL) between day 13 and 60, was performed.
No significant changes due to estradiol independent of CMS or vice
versa were found.
4. Discussion
We investigated whether stress may be a trigger that aggravates
depressive-like behavior in female estrogen-depleted rats, as such a
combination of stress and estrogen depletion might be responsible for
the increased risk of developing depression in women going through
menopause. Our results showed that a reduction in circulating estro-
gens increased body weight, reduced uterus and adrenal gland weight,
increased depressive-like behavior and changed glucose metabolism in
several brain regions. Contrary to our hypothesis, we did not find any
effect of chronic stress, neither in estrogen depleted, nor in estrogen
replaced animals.
In this study the OFT did not show any effect of estrogen depletion
on locomotion or anxiety-like behavior. The FST, however, showed
depressive-like behavior in rats after 2months of estrogen depletion,
but not yet after 2 weeks. Other studies have shown similar results,
although the time interval between ovariectomy and the observed ef-
fects in the FST seems to vary among studies. Some studies found sig-
nificant differences in immobility time in the FST already 1 week
(Estrada-Camarena et al., 2011; Rachman et al., 1998), 2 weeks (Bekku
et al., 2006; Benmansour et al., 2016; Ibrahim et al., 2016), 3 weeks
(Bekku et al., 2006; Vega-Rivera et al., 2015) and 4 weeks after ovar-
iectomy (Vega-Rivera et al., 2015). Other studies did not find any sig-
nificant changes in the FST after 3 and 12 weeks (Estrada-Camarena
et al., 2011) or 4-months of estrogen depletion (Fedotova et al., 2016).
The differences between studies suggest that species differences, age,
latency between ovariectomy and start of the estradiol treatment, type
of estradiol administration, and differences in behavioral analysis could
affect the response to ovariectomy-induced estrogen depletion in the
FST. This complicates extrapolation of animal results to humans.
Fig. 4. [18F]FDG PET Whole brain. A. Whole brain [18F]FDG uptake, as a surrogate marker of glucose metabolism, on day 13 (n= 16 per group). B. Representation
of changes in [18F]FDG uptake in brain regions due to short-term estrogen depletion of 13 days. C. Whole brain [18F]FDG uptake, as a surrogate marker of glucose
metabolism, on day 60 (n=16 per group). D. Representation of changes in [18F]FDG uptake in brain regions due to estrogen depletion and chronic mild stress (CMS)
(n=8 per group).
Table 2
Analysis of [18F]FDG PET at day 13. Changes in [18F]FDG uptake (SUV) in the brain 13 days post ovariectomy (OVX).
Decrease of [18 F]FDG uptake by OVX
Group comparison Cluster p-value Brain area T-value peak level Effect size (d-value)
EST > OVX <0.001 Midbrain, Thalamus, cerebellum, hippocampus, Brainstem 5.61 2.08
Increase of [18 F]FDG uptake by OVX
Group comparison Cluster p-value Brain area T-value peak level Effect size (d-value)
EST < OVX <0.05 Brainstem 6.24 2.32
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Besides behavioral changes, the current study showed differences in
regional brain glucose metabolism due to depletion of circulating es-
trogen levels. Regional reductions in brain glucose metabolism after 13
days of estrogen depletion were observed in cortical and subcortical
regions, and also in the cerebellum. Since no behavioral changes were
observed at this stage, these metabolic changes cannot be directly
linked to either anxiety-like or depressive-like behavior. Differences in
[18F]FDG uptake in specific brain areas were also found after 2months
of estrogen depletion. The majority of brain regions with increased
glucose metabolism as a consequence of a prolonged reduction in es-
trogen levels, such as insular cortex and frontal cortex, are involved in
cognition and emotion, suggesting that estrogen has an effect on cog-
nitive and executive functions (Shamungan and Epperson, 2014).
In contrast to our hypothesis, chronic stress did not aggravate the
depressive-like behavior in estrogen-depleted animals in this study. The
applied chronic stress protocol has been shown to induce both de-
pressive-like behavior and anxiety-like behavior in rodents in other
studies. Previous studies with CMS models have reported an increase in
immobility in the FST and Tail Suspension test in female rodents
(Chandrasekhar et al., 2017; Dalla et al., 2008; Franceschelli et al.,
2015; Marco et al., 2017; Xing et al., 2013), and increases in anxiety
levels and locomotion in the OFT, Elevated plus maze and Marble
burying test (Chung et al., 2012; Franceschelli et al., 2015; Palumbo
et al., 2007). There are several plausible explanations for the absence of
an effect of CMS in our study. First, the animals might have become
habituated to the individual stressors, since the stressful events were
presented in a predictable order. Thus, animals could have experienced
these events as less stressful. Second, it has been suggested that the
effect of stress is less robust in females than in males (Dalla et al., 2005;
Franceschelli et al., 2014), although CMS induced differences in be-
havior has been observed in female rats as well (Dalla et al., 2008).
Third, the high variability and contradictory results amongst the dif-
ferent studies could be explained by the type of stressors the duration of
exposure to CMS, as CMS protocols lasting between 2 and 8 weeks have
been used (Willner, 2017a, 2017b).
In contrast, Hu and colleagues found CMS-induced changes in glu-
cose metabolism in areas like auditory and piriform cortex, and septal
nuclei (Hu et al., 2010). These contradictory results may be ascribed to
differences in the duration of the chronic stress, gender differences, and
the types of stressors used. Studies using other chronic stress models,
like chronic restraint stress (Wei et al., 2017) and chronic unpredictable
stress (Lin et al., 2014; Zhou et al., 2017), have also shown changes in
brain metabolism, although another study did not show any effect of
chronic unpredictable stress alone on glucose metabolism (Baptista
et al., 2015). Likely, differences in experimental environment, gender
differences and type of stress are relevant for possible effects on brain
metabolism.
Our study does not show any complementary effect of CMS on de-
pressively-like behavior induced by estrogen depletion. A potential
limitation of our study is that the CMS protocol was started 2 weeks
after OVX, when estrogen levels are stably reduced. Consequently, the
study design may mimic the effect of chronic stress on postmenopausal
women, rather than peri-menopausal women with changing estrogen
levels. By performing the CMS protocol around the day of OVX, the
model will likely be better able to show the interaction between chronic
stress and declining estrogen levels. In addition, more research in this
Table 3
Analysis of [18F]FDG PET at day 60. Changes in [18F]FDG uptake (SUV) in the brain at 60 days post ovariectomy (OVX) and 48 days of chronic mild stress (CMS)
exposure.
Decrease of [18 F]FDG by OVX effect on stressed animals
Group Comparison Cluster p-value Brain area T-value (mean ± SD) Effect size (d-value)
EST > VEH <0.001 Orbitofrontal cortex, Piriform cortex - amygdala complex, Insular cortex 8.51 4.72
EST > VEH+CMS <0.001 Orbitofrontal cortex, Piriform cortex - amygdala complex, Frontal association
cortex
7.21 4.00
EST+CMS > VEH <0.05 Orbitofrontal cortex, Frontal association cortex 5.71 3.17
EST+CMS > VEH+CMS <0.05 Orbitofrontal cortex, Frontal association cortex 6.00 3.33
<0.05 Orbitofrontal cortex 5.90 3.27
<0.05 Midbrain, Hippocampus 5.35 2.97
Increase of [18F]FDG by OVX effect on stressed animals
Group comparison Cluster p-value Brain area T-value (peak) Effect size (d-value)
EST < VEH <0.05 Hypothalamus 5.55 3.08
< 0.05 Entorhinal cortex 5.44 3.02
< 0.05 Entorhinal cortex 4.77 2.65
EST < VEH+CMS <0.001 Brainstem 6.45 3.58
< 0.05 Entorhinal cortex 6.93 3.84
< 0.05 Midbrain 6.90 3.83
< 0.05 Entorhinal cortex 5.46 3.03
EST+CMS < VEH <0.001 Entorhinal cortex, Auditory temporal parietal cortex, Visual cortex, Hippocampus 7.70 4.27
< 0.05 Entorhinal cortex, Auditory temporal parietal cortex 5.26 2.92
EST+CMS < VEH+CMS <0.01 Brainstem 7.13 3.96
< 0.01 Brainstem 5.40 3.00
< 0.01 Entorhinal cortex, Auditory temporal parietal cortex 4.93 2.73
< 0.05 Entorhinal cortex, Auditory temporal parietal cortex 4.58 2.54
Table 4
Within group analysis of [18F]FDG PET. Changes in [18F]FDG uptake (SUV) in the brain between first PET scan (13 days after ovariectomy) and second PET scan
(after 48 days of chronic mild stress CMS exposure).
Within group decrease of [18F] FDG uptake
Group Brain area Day 16 (average± SEM) Day 60 (average± SEM) p-value Effect size (d value)
EST+CTL Brainsteam 2.3± 0.1 1.9±0.1 < 0.05 1.19
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field is needed to determine which other variables can be affecting the
susceptibility of women to get psychiatric disorders during menopause
or hormone therapy. Additional studies in animal models are also
needed to increase our understanding of the central effects of the de-
cline in circulating estrogen levels during menopause, the effect of
hormonal replacement therapy, and the possible influence of chronic
stress.
5. Conclusion
Reduced levels of estrogen as a consequence of ovariectomy can
induce depressive-like behavior and changes in glucose metabolism in
brain areas involved in cognition and emotion. CMS did not showed any
significant contribution to the magnitude of depressive-like symptoms,
or to brain metabolism in our study. However, more studies with dif-
ferent stress models are needed to gain more insight in the role of stress
in the development of depression related to estrogen changes.
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